Table 1. Patient clinical characteristics.
| University of Graz | University of Zurich | ||||
|---|---|---|---|---|---|
| N = 657 | N = 349 | ||||
| Number (%missing) | Percentage | Number (%missing) | Percentage | ||
| Median Age, years | 35.9 | 34.9 | |||
| Histology | (1.4%) | (0.6%) | |||
| Seminoma | 388 | 59.9 | 197 | 56.8 | |
| Nonseminoma | 260 | 40.1 | 150 | 43.2 | |
| Clinical tumor stage | (2.6%) | (0.0%) | |||
| Stage IA-B | 463 | 72.3 | 226 | 64.8 | |
| Stage IS | 9 | 1.4 | 9 | 2.6 | |
| Stage IIA-IIC | 98 | 15.3 | 50 | 14.3 | |
| Stage IIIA-C | 70 | 10.9 | 64 | 18.3 | |
| IGCCCG risk group | (0.0%) | (7.3%) | |||
| Good | 137 | 76.1 | 77 | 67.6 | |
| Intermediate | 19 | 10.6 | 21 | 18.4 | |
| Poor | 24 | 13.3 | 16 | 14.0 | |
| VTE events | 34 | 5.2 | 18 | 5.2 | |
| Primary Thromboprophylaxis | 22 | 3.3 | 7 | 2.0 | |
IGCCCG, International Germ Cell Cancer Collaborative Group; VTE, venous thromboembolism.